NYSE: BIOA STOCK INFORMATION

Select from the drop-down menu below to view the latest trading information on our common stock and warrants, which are both traded on the New York Stock Exchange (NYSE:BIOA and NYSE:BIOA.WS respectively).

NYSE: BIOA STOCK INFORMATION

Back to Top

ANALYST COVERAGE

ANALYST COVERAGE
John Quealy / Chip Moore Canaccord Genuity +1 (617) 371-3837/3879
Alex Stewart Barclays +44 (0) 7880 093219
Peter Clark Société Générale +44 20 7762 5084
Amit Dayal Rodman & Renshaw +1 (212) 356-0517
Back to Top

SEC FILINGS

SEC FILINGS

View all SEC filings

 

 

Loading data...
Back to Top

CORPORATE PRESENTATIONS

CORPORATE PRESENTATIONS
BioAmber Corporate Presentation
BioAmber Corporate Video
BioAmber Sarnia Plant Slideshow
Download Transcript of Earnings Call Webcast
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
  • BioAmber Sarnia
prev prev
Back to Top

LEADERSHIP & GOVERNANCE

LEADERSHIP & GOVERNANCE

BioAmber has assembled a team of industry veterans in the fields of industrial biotechnology and chemicals. Having assembled unmatched experience and unrivalled technical and business acumen, BioAmber is positioned to lead the emergence of economically-viable, sustainable chemicals. The company has staffed its board of directors and management team with seasoned professionals possessing strong track records and complementary experience.

Directors

Raymond J. Land Chairman
 
Kurt Briner
 
Heinz Haller
 
Jean-François Huc
 
Ellen B. Richstone
 
Kenneth W. Wall
 
George F.J. Gosbee
 

Senior Management

Jean-François Huc
 
R. Laurent Bernier
 
Thomas Desbiens
 
Mike Hartmann
 
Mario Saucier
 
James Millis
 
Fabrice Orecchioni
 

Board Committees

The management team is to promote sustainable development, ownership of issues, proper behavior, and innovative technology, all of which foster eco efficiency and a safe working environment. We are firmly committed to the pursuit of HSE excellence – not just for today but for the future.

The Company’s Board of Directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee, each of which operates pursuant to a charter adopted by our board of directors.

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.

  Audit Committee Compensation Committee Nominating and Corporate Governance Committee
Kurt Briner   member chair
Heinz Haller member chair  
Raymond J. Land chair member  
George F.J. Gosbee   member member
Ellen B. Richstone member   member
Kenneth W. Wall member   member
Board Committees & Governance

Back to Top

Previous
  • Raymond J. Land

    Raymond J. Land

    Chairman

    Raymond Land joins BioAmber as an independent board member and Chair of the audit committee.  Ray has over 35 years financial experience and has been the Chief Financial Officer of four publicly traded companies: Clarient (CLRT), Orchid Cellmark (ORCH), Genencor (GCOR) and West Pharmaceutical Services (WST).  He was formerly the Vice President-Corporate Controller and then a Vice–President General Manager of Campbell Soup Co.’s Frozen Food Division.  Ray has also been the audit committee chair for several private and public companies. Ray has extensive experience in assisting start-ups put in place the financial organizations, systems and procedures needed to manage rapid growth and ensure compliance. Ray is a certified public accountant and spent 9 years at Coopers & Lybrand.

  • Kurt Briner

    Kurt Briner

     

    Kurt Briner is an independent consultant to pharmaceutical and biotechnology companies. He has over 30 years of experience in the pharmaceutical industry. Mr Briner is the former President and Chief Executive Officer of Sanofi Pharma S.A. in Paris, France, a position he held from 1988 until his retirement in 2000.

    Mr. Briner was a director of Novo Nordisk and Galenica S.A. (Switzerland) and is an active Board member of Progenics Pharmaceuticals Inc. (USA) Mr. Briner holds a Diploma of the Commercial Schools of Basel and Lausanne, Switzerland.

  • Heinz Haller

    Heinz Haller

    Executive

    Heinz Haller joins BioAmber as an independent board member with over 25 years of experience in the chemical industry. Heinz is Executive Vice President of The Dow Chemical Company, and President of Dow Europe, Middle East, Africa and India. He is also the chairman of the board of Dow Kokam, a lithium ion battery JV with Townsend Ventures. He also sits on the board of Advanced Electrolytes, a JV between Dow and Ube Industries of Japan and serves on the board of Dow Corning, a JV between Dow and Corning, as the lead director for Dow. Heinz is a member of Dow’s Executive Leadership Committee and co‐chairs the Growth and Innovation Team with the CTO of Dow. Prior to his present responsibilities he was responsible for the Performance Materials Division of DOW. Heinz is a former CEO of OMYA/Pluess-‐Stauffer, a privately held company active in chemical distribution and the world’s largest calcium carbonate mining company. Heinz is a former CEO of Red Bull Sauber AG and Sauber Petronas Engineering AG, and a former Managing Director of Allianz Capital Partners GmbH.

  • Jean-François Huc

    Jean-François Huc

    President & CEO

    Jean-François Huc is BioAmber’s CEO. Prior to BioAmber, he was the Chief Operating Officer of Diversified Natural Products (DNP), where oversaw the spin off of the succinic acid assets, at which time he stepped down from DNP to become President and CEO of BioAmber.  Prior to DNP Mr. Huc was CEO of TGN Biotech, a company producing recombinant proteins in transgenic animals.  Prior to TGN, he was the founder and CEO of MedExact, a startup offering web-based promotional services to pharmaceutical companies in the US and France.  Mr. Huc is a former Vice President of Alliance Management for Sanofi-Synthelabo, based in Paris, where he managed the company's global strategic alliances. Prior to Sanofi, he was a Partner with Arthur D. Little, a management consulting firm and Director of its French healthcare practice.   Mr. Huc has an M.B.A. from York University in Toronto and an undergraduate degree in biochemistry from the University of Western Ontario.

  • Ellen B. Richstone

    Ellen B. Richstone

    Executive

    Ms. Richstone was the Chief Financial Officer of several public and private companies between 1989 and 2012, including Rohr Aerospace (a Fortune 500 Company). From 2002 to 2004, Ms. Richstone was the President and Chief Executive Officer of the Entrepreneurial Resources Group. From 2004 until its sale in 2007, Ms. Richstone served as the financial expert on the board of directors of American Power Conversion. Ms. Richstone currently serves on the boards of three public companies: Bioamber, eMagin (NYSE: EMAN); Everyware Global (NASDAQ: EVRY) and on the boards of both private corporations and non profits including the National Association of Corporate Directors-New England. She chairs the Audit Committees of both eMagin and Everyware Global. In April 2013, Ms. Richstone was given the first annual Distinguished Director Award from the Corporate Directors Group. Ms. Richstone graduated from Scripps College in Claremont California and holds graduate degrees from the Fletcher School of Law and Diplomacy at Tufts University. Ms. Richstone also completed the Advanced Professional Certificate in Finance at New York University’s Graduate School of Business Administration and attended the Executive Development program at Cornell University’s Business School. Ms. Richstone holds an Executive Master’s Certification in Director Governance from the American College of Corporate Directors. We believe that Ms. Richstone’s broad industry experience in technology, industrial and cleantech, as well as her financial and corporate governance expertise will make her a valuable member of our board of directors.

     

  • Kenneth W. Wall

    Kenneth W. Wall

     
    Kenneth W. Wall has served on our board of directors since August 2013. Mr. Wall previously served as BioAmber's Chief Operations Officer from October 2012 to June 2013, and as BioAmber’s Senior Vice President of Manufacturing from 2011 to October 2012. From 2005 to 2011, Mr. Wall was a consultant to the chemical industry, and prior to that served in various management positions at INVISTA and DuPont. Mr. Wall holds a Ph.D. in chemical engineering from the University of Missouri-Rolla, a Master of Science in chemical engineering from the University of Missouri-Rolla and a Bachelor of Science in chemical engineering from the University of Missouri-Rolla.
  • George F.J. Gosbee

    George F.J. Gosbee

    Mr. Gosbee's career spans over 20 years in corporate finance, investment banking, global capital markets and advisory. Prior to founding AltaCorp Capital in 2010, Mr. Gosbee was Chairman, President and CEO of Tristone Capital Global Inc., a global energy investment firm which he founded. Tristone became the largest global independent energy advisory firm and was acquired by an international bank in 2009. His current firm, AltaCorp Capital, is an advisory firm that is partnered with Alberta Treasury Branch (ATB Financial), a wholly owned subsidiary of the Government of Alberta.

    Mr. Gosbee is a former Governor of the National Hockey League (NHL). He led a group to purchase the Arizona Coyotes and restructure the Club. Currently he is an Alternate Governor on the NHL Board of Governors and Co-owner of the Arizona Coyotes.

    Mr. Gosbee was the Vice Chairman of Alberta Investment Management Co (AIMCo) and was called on to assist in the creation of the crown corporation. He spent 8 years as the Vice Chair of AIMCo, which is a $90 billion institutional investment fund, and currently is a Director. Mr. Gosbee is a former Director of the TMX Group and a former Board Member of Chrysler Group LLC in Detroit, where he served on behalf of both the Canadian Federal and Provincial (Ontario) governments to oversee their collective investment in the company and assist in the restructuring.

Next
Previous
  • Jean-François Huc

    Jean-François Huc

    President & CEO

    Jean-François Huc is BioAmber’s CEO. Prior to BioAmber, he was the Chief Operating Officer of Diversified Natural Products (DNP), where oversaw the spin off of the succinic acid assets, at which time he stepped down from DNP to become President and CEO of BioAmber.  Prior to DNP Mr. Huc was CEO of TGN Biotech, a company producing recombinant proteins in transgenic animals.  Prior to TGN, he was the founder and CEO of MedExact, a startup offering web-based promotional services to pharmaceutical companies in the US and France.  Mr. Huc is a former Vice President of Alliance Management for Sanofi-Synthelabo, based in Paris, where he managed the company's global strategic alliances. Prior to Sanofi, he was a Partner with Arthur D. Little, a management consulting firm and Director of its French healthcare practice.   Mr. Huc has an M.B.A. from York University in Toronto and an undergraduate degree in biochemistry from the University of Western Ontario.

  • R. Laurent Bernier

    R. Laurent Bernier

    Senior VP
    Until the recent spin-off of BioAmber Inc. from Diversified Natural Products, Laurent BERNIER was Vice President R&D working on the restructuring of DNP’s succinic acid division more particularly on the management of its IP portfolio and various scientific and business partnerships. Prior to joining BioAmber and Diversified Natural Products, Dr. BERNIER was Vice President Eastern Canada for Foragen Technology Management Inc., a venture capital fund created to help commercialize early-stage, advanced agricultural technologies from Canadian sources. Before Foragen, he was the founding Executive Director of BioNB (formerly known as BioAtlantech), New-Brunswick’s lead agency for the development of the bio-industries and had been previously Vice President Life Sciences for Inno-centre, a Montreal-based organization dedicated to helping advanced technology entrepreneurs start up commercial ventures. As an industrial researcher, Laurent BERNIER has held various research and managerial positions at C-I-L, ICI Canada and Zeneca BioProducts, where he directly contributed to the discovery, development and launch of five biotechnology-related products and services. He is listed as an inventor of a dozen biotechnology related patents and has published extensively in the area of agricultural and forestry biotechnology. Dr. Bernier has held various adjunct professorships and has been a guest lecturer at several Canadian universities. He received his Ph.D. in Microbiology and Immunology from the University of Montreal. He was a recipient of an INSERC industrial post-doctoral fellowship conducted at FPInnnovations (formerly the Pulp and Paper Research Institute of Canada or PAPRICAN) in collaboration with McGill University in Montreal. He is currently Chairman of the Board of CRIBIQ (QC) and AIREX Énergie inc.
  • Thomas Desbiens

    Thomas Desbiens

    General Counsel

    Thomas Desbiens is a business and intellectual property lawyer with more than twenty years of experience as partner in a boutique law firm, who oversees BioAmber’s legal matters, including its corporate & commercial transactions, financing activities, strategic partnerships and securities compliance & corporate governance matters.

    He has extensive national and international expertise in assisting fast growing companies involved in complex technological environments, and representing numerous companies in connection with venture capital & debt financings, initial public offerings, merger & acquisition transactions, strategic alliances, commercial & licensing agreements and corporate governance matters.

  • Mike Hartmann

    Mike Hartmann

    Executive VP
    Mike Hartmann was previously responsible for the institutional sales and trading desk for CIBC World Markets in Montreal. His ten year career started in sales with CIBC WM and was promoted to Executive Director and oversaw the institutional equity sales and trading desk. He helped initiate and was the co-chairman of one of Canada's premier institutional conference for seven years. During his time at CIBC WM, over a billion dollars in equity was raised through IPOs, secondary offerings and bought deals for the Montreal office that was part of billions raised in equity over his career at CIBC WM. Prior to that, he was an institutional sales representative with Sprott Securities that specialized in small cap, fast growing companies. Mr. Hartmann is the Treasurer of the Canadian Andover Fund, providing scholarships to qualified students in Canada to attend Andover prep school in Andover MA. He has an International MBA from York University and received his BA from Rollins College in FL with a major in Economics.
  • Mario Saucier

    Mario Saucier

    CFO
    Mario Saucier joined BioAmber as Chief Financial Officer in January 2016. He comes to us as a skilled financial executive with extensive on-point skills as well as strong leadership and financial insight in large and medium international publicly traded companies. In his role as CFO, Mr. Saucier’s focus will be in overseeing the financial function of the company including treasury, budget planning, investor relations and information systems.

    He carries over 20 years of experience in senior financial and operational positions including his most recent role from May 2014 until November 2015 as CFO of Norduyn. While serving as CFO, Mr. Saucier also acted as President for Transtex Composite, a subdivision of Norduyn.

    Prior to Norduyn, he served as CFO at Englobe Corp., a bio-remediation Company where he accomplished the restructuring and refinancing of the firm as well as attained the mandate of privatising the company, all within a 24 month period. This achievement brought him to be appointed as interim Chief Executive Officer for a six month period with Englobe Corp. Previous positions also include Senior Vice President of Finance and Chief Accounting Officer of Quebecor World, Vice President Strategy & Performance of Total Transit System, a division of Bombardier Transportation, as well as Vice President Implementation SAP leading the largest SAP project in Canada.

    Mr. Saucier holds a B.B.A. from the Université du Québec à Montréal and has been a member of the Canadian Institute of Chartered Accountants since 1991.
  • James Millis

    James Millis

    CTO
    James Millis, CTO, has worked in the field of industrial biotechnology for 30 years. Mr. Millis most recently served as CEO of Draths Corporation. His prior appointment was as Technical Director for Cargill's Industrial Bioproducts business unit, during which time new chemical businesses were created in biobased urethane polyols and in the application of metathesis chemistry, the latter now Elevance. Earlier positions included business and technical leadership roles at Maxygen and Bio-Technical Resources. Mr. Millis has been involved in the commercial development and scale-up of several technologies, spanning fermentation and chemical catalysis, and is co-inventor on 12 US patents and their foreign equivalents.
  • Fabrice Orecchioni

    Fabrice Orecchioni

    COO
    Fabrice Orecchioni is BioAmber’s Chief Operations Officer. In his role, he oversees engineering, procurement and construction activities (EPC), as well as overall operations, including manufacturing and supply chain. Fabrice joined BioAmber in January 2012 and served as Plant Manager and Sr VP, Operations. Prior to BioAmber, Mr. Orecchioni was Plant Manager at Abengoa Bioenergy where he was in charge of the start-up and operation of Abengoa's French BioFuel Facility during 5 years. Fabrice also spent 10 years in Amino Acids Fermentation business at Tate & Lyle and Ajinomoto Foods Europe through various positions around Process and Operations management. Mr. Orecchioni holds an Executive Master of Business Administration from HEC Paris, a degree in Bio-Process Engineering from École de Biologie Industrielle, and a degree in Chemistry from Université Pierre-et-Marie-Curie.
Next

Archives: Search / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

Nov 3, 2016

BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced financial and operational results for the three months ending September 30, 2016. Highlights Q3 2016 Sales of...

More
Oct 24, 2016

BioAmber Inc. (NYSE:BIOA) today announced that it will report financial results for the third quarter 2016 on Thursday, November 3, 2016 after the close of the market. The company has scheduled a...

More
Sep 21, 2016

If approved, the $360 million loan guarantee will be used to fund BioAmber's next plant MINNEAPOLIS, Sept. 21, 2016 /CNW Telbec/ - BioAmber Inc. (NYSE: BIOA) is pleased to announce an important...

More
 

print email rss

CALENDAR & EVENTS

CALENDAR & EVENTS
Wednesday, April 6, 2016 - Thursday, April 7, 2016
Wednesday, March 16, 2016 - Thursday, March 17, 2016
Monday, March 14, 2016 - Thursday, March 17, 2016
Tuesday, March 8, 2016 - Thursday, March 10, 2016
Tuesday, February 23, 2016 - Thursday, February 25, 2016
Back to Top

VISION FOR GROWTH

VISION FOR GROWTH

Accelerating the global adoption of green chemicals

Our Strategic Priorities
  • Rapidly Expand Global Manufacturing Capacity
  • Target the Large and Established 1,4 Butanediol Market
  • Develop Next-Generation Succinic-Derived Products
  • Reduce Production Costs (Continuous Improvement)
  • Expand Product Portfolio to Additional Building Block Chemicals
Back to Top